Clin2
NCT07210112Possibly a fitNot yet recruiting

Psilocybin and Trazodone for tough-to-treat depression

Depression - Major Depressive DisorderTreatment-resistant Depression (TRD)

Treatments studied

Part of Mental health clinical trials.

This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
112 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have depression without psychosis or hallucinations.
  • At least two different antidepressants haven't worked for you.
  • Your depression is moderate to severe (score of 20 or higher on a depression scale).
  • You are not currently taking certain medications like lithium, antipsychotics, or opioids.
  • You don't have a history of bipolar disorder, schizophrenia, or other major mental health conditions.
  • You haven't used psychedelics in your current depressive episode.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07737990Enrolling by invitation
Psilocybin group therapy for treatment-resistant depression

This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.

Toronto, Ontario
NCT07566104Not yet recruiting· Phase 2
Group therapy with psilocybin for depression

This study tests whether psilocybin—a psychedelic compound—combined with group therapy can help people with depression. Participants receive guided psilocybin sessions at UCLA and attend group therapy to process the experience.

Los Angeles, California
NCT06442423Recruiting· Phase 1
Psilocybin study for people with psychiatric symptoms

This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.

New Haven, Connecticut
NCT06512220Recruiting· Phase 2
Psilocybin for treatment-resistant depression brain imaging study

This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.

Toronto, Ontario
NCT06378229Recruiting· Phase 2
Psilocybin for hospitalized treatment-resistant depression

This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.

Ghent, Oost-Vlaanderen
NCT06132178Recruiting· Phase 2
Psilocybin and rTMS for hard-to-treat depression

This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.

Austin, Texas

Hear when a new Depression - Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.